• Company
• Rolontis and Leclaza make their place in Korea
• by Chon, Seung-Hyun Nov 29, 2022 05:54am

• Opinion
• [Reporter's view] Opinions surrounding the multinational ERP
• by Eo, Yun-Ho Nov 29, 2022 05:54am

• Policy
• First Forxiga follow-on Dapapro listed at KRW 684
• by Lee, Tak-Sun Nov 29, 2022 05:54am

• Company
• Keytruda has booked high sales in the domestic market
• by Chon, Seung-Hyun Nov 29, 2022 05:53am

• Policy
• Avastin biosimilar will be reimbursed starting next month
• by Lee, Tak-Sun Nov 29, 2022 05:53am

• Company
• First targeted PIK3CA Piqray reapplies for reimb
• by Eo, Yun-Ho Nov 28, 2022 05:51am

• Policy
• Actilyse's price to rise 15% from next month
• by Kim, Jung-Ju Nov 28, 2022 05:50am

• Opinion
• [Reporter's view]There should be no recurrence of COVID kit
• by Lee, Hye-Kyung Nov 28, 2022 05:50am

• Policy
• Crysvita, referred to the welfare committee
• by Lee, Jeong-Hwan Nov 28, 2022 05:50am

• Policy
• IVI-Biovac has signed an agreement to develop an OCV
• by Lee, Hye-Kyung Nov 28, 2022 05:49am